Inhibikase Therapeutics Inc [IKT] stock prices are up 3.70% to $2.52 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IKT shares have gain 7.23% over the last week, with a monthly amount glided 123.01%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
The stock price of Inhibikase Therapeutics Inc [IKT] has been fluctuating between $0.80 and $3.82 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Inhibikase Therapeutics Inc [NASDAQ: IKT] shares were valued at $2.52 at the most recent close of the market. An investor can expect a potential return of 98.41% based on the average IKT price forecast.
Analyzing the IKT fundamentals
The Inhibikase Therapeutics Inc [NASDAQ:IKT] reported sales of 0.08M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at -238.85%, Pretax Profit Margin comes in at -231.02%, and Net Profit Margin reading is -231.02%. To continue investigating profitability, this company’s Return on Assets is posted at -2.08, Equity is -1.94 and Total Capital is -3.71. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.41 points at the first support level, and at 2.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.63, and for the 2nd resistance point, it is at 2.73.
Ratios To Look Out For
It’s worth pointing out that Inhibikase Therapeutics Inc [NASDAQ:IKT]’s Current Ratio is 2.32. Also, the Quick Ratio is 2.32, while the Cash Ratio stands at 0.83. Considering the valuation of this stock, the price to sales ratio is 234.99, the price to book ratio is 3.57.
Transactions by insiders
Recent insider trading involved Bellini Roberto, Director, that happened on Oct 21 ’24 when 1.46 million shares were purchased. Director, Kush Arvind completed a deal on Oct 21 ’24 to buy 0.14 million shares. Meanwhile, Director Munshi Amit bought 0.36 million shares on Oct 21 ’24.
